{"doi":"10.1055/a-2536-9161","title":"Left Ventricular Assist Device in the Management of Heart Failure: A Single-Center Experience","abstract":"Background: Heart failure is a prevalent health care issue in the United States. While most cases of heart failure can be managed medically, intractable cases benefit from a left ventricular assist device (LVAD). Aim: The aim of this study is to review the outcomes of LVAD therapy at the University of Kentucky. Materials and Methods: Data received from University of Kentucky Hospital. We received Institutional Review Board approval to review patient records admitted for LVAD implantation from January 1, 2017, to December 31, 2021. Results: After reviewing records, we had 127 eligible LVAD patients with an age range of 18 to 83 years, with 87% of recipients being white, 12.5% being black, 81% male, and 19% female. Results show the average length of admission for patients receiving LVAD is 41 days. Quality of life is reported using the New York Heart Association (NYHA) classification at follow-up, which shows 6 patients in Class I, 52 patients progressing to Class II, 21 patients to class III; other patients were deceased before discharge or did not go below class IV heart failure. Prior to 2021, there were 105 patients and 65 patients were alive at 2 years follow-up, and 18 out of 23 patients who received LVAD after 2021 are still living. For postoperative complications, 26% developed stroke, 24.4% developed gastrointestinal bleeding, 26% developed renal failure, 44.8% developed respiratory failure, 37% developed driveline infection, 14.2% developed right ventricular dysfunction/failure, and 20.4% developed an LVAD complication. Conclusion: LVAD has been implemented to manage advanced heart failure and improve quality of life.","journal":"International Journal of Angiology","year":2025,"id":525338,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9356,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1400499,"name":"R. Malyala","orcid":null,"position":1,"is_corresponding":false},{"id":1100327,"name":"Sibu P. Saha","orcid":"0000-0003-4275-3265","position":2,"is_corresponding":false},{"id":1400498,"name":"Sam Karem","orcid":null,"position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-19T02:50:21.274116Z","pmid":"40771292","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}